Acurx Pharmaceuticals Inc. (ACXP)
NASDAQ: ACXPHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ACXP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.95M
- EPS (TTM)
- -$2.67
- Dividend yield
- None
- 52-week range
- 1.23 – 7.98
- Day range
- 1.24 – 1.28
- Volume / Avg
- 74.06K / 125.08K
- Beta
- —
- Shares outstanding
- 5.56M
52-week range
ACXP stock today
Acurx Pharmaceuticals (ACXP) closed at $1.25 on Oct 8, down 3.85% (-$0.05), versus the S&P 500's 0.47% decline. At this level, ACXP sits near the bottom of its 52-week range of $1.23 to $7.98: 84.3% below the high and 1.6% above the low. Acurx Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.67), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Acurx Pharmaceuticals
Company profileAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. David P. Luci C.P.A., Esq., J.D.
- Headquarters
- Staten Island, NY
- Employees
- 4
- IPO year
- 2021
- Website
- acurxpharma.com
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$17.00+1260.00%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Acurx Pharmaceuticals peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| APREAprea Therapeutics Inc. | 0.5582 | -7.74% | $7.03M | vs ACXP |
| BOLTBolt Biotherapeutics Inc. | 3.65 | +1.39% | $7.03M | vs ACXP |
| ENVBEnveric Biosciences Inc. | 1.52 | +1.67% | $6.80M | vs ACXP |
| NRSNNeuroSense Therapeutics Ltd. | 3.58 | -6.28% | $6.79M | vs ACXP |
| LEXXLexaria Bioscience Corp. | 3.20 | -8.57% | $6.74M | vs ACXP |
| AIMAIM ImmunoTech Inc. | 0.1796 | -1.75% | $7.17M | vs ACXP |
| XCURExicure Inc. | 1.00 | -1.96% | $6.55M | vs ACXP |
| CELZCreative Medical Technology Holdings Inc. | 0.8604 | -2.45% | $6.53M | vs ACXP |
Indexes, lists and sector
Appears in lists
Acurx Pharmaceuticals stock FAQ
What is Acurx Pharmaceuticals's stock price today?
ACXP last traded at $1.25 as of Oct 8, 4:00 PM EDT, down 3.85% on the day. Prices are delayed at least 15 minutes.
Who is Acurx Pharmaceuticals's CEO?
Mr. David P. Luci C.P.A., Esq., J.D. is the chief executive officer of Acurx Pharmaceuticals Inc., which has about 4 employees.
What is the ACXP 52-week high?
The 52-week high for ACXP is $7.98 and the 52-week low is $1.23. The stock is currently 84.3% below its high.